Glyn Edwards

Chairman at VacV Biotherapeutics Limited

Presenter

VacV Biotherapeutics is developing next generation oncolytic viruses for solid tumors. Our lead product BioTTT001 is in Phase 1 studies in China and has reported improved outcomes, including complete responses in refractory brain cancers. We expect further clinical data from our lead program in 2025. We expect to open a US IND in 2025 for BioTTT001. Our second product, VacV001 is designed to be given systemically will enter the clinic in 2025 in Europe. We are looking to raise a pre-IPO round in Q1 2025 and are planning for a NASDAQ IPO in 2026. The company is based in London and carries out R&D in London and China.